Browse our 650+ Publications​

Latest Publications

AIRE expression controls the peripheral selection of autoreactive B cells

Sng et al.
Science Immunology
April 2019
Authors and Affiliates
Sng J1, Ayoglu B2, Chen JW1, Schickel JN1, Ferre EMN3, Glauzy S1, Romberg N4,5, Hoenig M6, Cunningham-Rundles C7, Utz PJ2,8, Lionakis MS3, Meffre E9 1 Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA. 2 School of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, CA 94305, USA. 3 Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD USA. 4 Division of Immunology and Allergy, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 5 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6 Department of Pediatrics, University Medical Centre Ulm, Ulm, Germany. 7 Division of Allergy and Immunology, Department of Medicine, Icahn School of Medicine, Mount Sinai, New York, NY 10029, USA. 8 Institute for Immunity, Transplantation, and Infection (ITI), Stanford University, Stanford, CA 94305, USA. 9 Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA. eric.meffre@yale.edu.

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease

Whangbo et al.
Blood Advances
April 2019
Authors and Affiliates
Whangbo JS1,2,3,4, Kim HT5,6, Nikiforow S3,4, Koreth J3,4, Alho AC3,4,7, Falahee B3,4, Kim S3,4, Dusenbury K3,4, Fields MJ3,4, Reynolds CG3,4, Alyea EP 3rd3,4, Armand P3,4, Cutler CS3,4, Ho VT3,4, Antin JH3,4, Soiffer RJ3,4, Ritz J3,4 1 Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA. 2 Department of Pediatric Oncology and. 3 Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA. 4 Harvard Medical School, Boston, MA. 5 Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA. 6 Harvard School of Public Health, Boston, MA; and. 7 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy

Gerevini et al.
Multiple Sclerosis
April 2019
Authors and Affiliates
Gerevini S1, Capra R2, Bertoli D3, Sottini A4, Imberti L4; Department of Neuroradiology, IRCCS San Raffaele Hospital, Milan, Italy. 2 Multiple Sclerosis Center, ASST Spedali Civili di Brescia, Brescia, Italy. 3 Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy/Centro di Ricerca Emato-oncologica AIL (CREA), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy. 4 Centro di Ricerca Emato-oncologica AIL (CREA), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.

Mobilization of CD8þ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer

Seo et al.
Clinical Cancer Research
April 2019
Authors and Affiliates
Seo YD1, Jiang X#1, Sullivan KM#1, Jalikis FG2, Smythe KS3, Abbasi A1, Vignali M4, Park JO1, Daniel SK1, Pollack SM3, Kim TS1, Yeung R1, Crispe IN2, Pierce RH3, Robins H3,4, Pillarisetty VG5; 1Department of Surgery, University of Washington, Seattle, Washington. 2 Department of Pathology, University of Washington, Seattle, Washington. 3 Fred Hutchinson Cancer Research Center, Seattle, Washington. 4 Adaptive Biotechnologies, Seattle, Washington. 5 Department of Surgery, University of Washington, Seattle, Washington. vgp@uw.edu. # Contributed equally

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

Agdashian et al.
Cancer Immunology and Immunotherapy
April 2019
Authors and Affiliates
Agdashian D1, ElGindi M1, Xie C1, Sandhu M1, Pratt D2, Kleiner DE2, Figg WD3, Rytlewski JA4, Sanders C4, Yusko EC4, Wood B5, Venzon D6, Brar G1, Duffy AG1, Greten TF7,8, Korangy F1. 1 Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Building 10, Room 3B43, Bethesda, MD, 20892, USA. 2 Laboratory of Pathology, Center for Cancer Research (CCR) National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 3 Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 4 Adaptive Biotechnologies, Seattle, WA, USA. 5 Center for Interventional Oncology, Radiology and Imaging Sciences and Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA. 6 Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 7 Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Building 10, Room 3B43, Bethesda, MD, 20892, USA. tim.greten@nih.gov. 8 NCI CCR Liver Cancer Program, Bethesda, MD, USA.

Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion

Sawant et al.
Nature Immunology
April 2019
Authors and Affiliates
Sawant DV1,2, Yano H1,3, Chikina M4, Zhang Q1,5, Liao M1,6, Liu C1, Callahan DJ1,3, Sun Z7, Sun T7, Tabib T8, Pennathur A9, Corry DB10, Luketich JD9, Lafyatis R8, Chen W7, Poholek AC1,11, Bruno TC1,12,13, Workman CJ1, Vignali DAA14,15,16; 1 Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2 Department of Inflammation and Oncology, Discovery Research, Amgen, South San Francisco, CA, USA. 3 Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4 Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 5 Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA. 6 The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. 7 Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA. 8 Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 9 Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 10 Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 11 Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 12 Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. 13 Cancer Immunology & Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. 14 Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dvignali@pitt.edu. 15 Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. dvignali@pitt.edu. 16 Cancer Immunology & Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. dvignali@pitt.edu.

IgG4‐related disease: Association with a rare gene variant expressed in cytotoxic T cells

Newman et al.
Molecular Genetics and Genomic Medicine
April 2019
Authors and Affiliates
Newman JH1, Shaver A2, Sheehan JH3, Mallal S4, Stone JH5, Pillai S6, Bastarache L7, Riebau D8, Allard-Chamard H6, Stone WM6, Perugino C6, Pilkinton M4, Smith SA4, McDonnell WJ4, Capra JA3, Meiler J3, Cogan J1,9, Xing K6, Mahajan VS6, Mattoo H6, Hamid R1,9, Phillips JA 3rd1,9; Undiagnosed Disease Network. 1 Vanderbilt Center for Undiagnosed Disease, Vanderbilt University, Nashville, Tennessee. 2 Department of Pathology, Microbiology and of Immunology, Vanderbilt University, Nashville, Tennessee. 3 Department of Biochemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee. 4 Department of Medicine, Center for Translational Immunology and Infectious Diseases, Vanderbilt University, Nashville, Tennessee. 5 Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 6 Ragon Institute of MGH, MIT and Harvard Medical School, Boston, Massachusetts. 7 BioVU, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee. 8 Department of Neurology, Vanderbilt University, Nashville, Tennessee. 9 Department of Pediatrics, Division of Medical Genetics, Vanderbilt University, Nashville, Tennessee.

Crossreactive public TCR sequences undergo positive selection in the human thymic repertoire

Khosravi-Maharlooei et al.
Journal of Clinical Investigation
March 2019
Authors and Affiliates
Khosravi-Maharlooei M1, Obradovic A1, Misra A1, Motwani K2, Holzl M1, Seay HR2, DeWolf S1, Nauman G1,3, Danzl N1, Li H1, Ho SH1, Winchester R4, Shen Y5, Brusko TM2, Sykes M1,3,6; Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA. 2 Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA. 3 Department of Microbiology and Immunology, Columbia University Medical Center, Columbia University, New York, New York, USA. 4 Division of Rheumatology, Department of Medicine. 5 Center for Computational Biology and Bioinformatics, and. 6 Department of Surgery, Columbia University Medical Center, Columbia University, New York, New York, USA.

Subclonal STAT3 mutations solidify clonal dominance

Kerr et al.
Blood Advances
March 2019
Authors and Affiliates
Cassandra M. Kerr,1 Michael J. Clemente,1 Peter W. Chomczynski,1 Bartlomiej Przychodzen,1 Yasunobu Nagata,1 Vera Adema,1 Valeria Visconte,1 Alan E. Lichtin,2 Satu Mustjoki,3,4 Tomas Radivoyevitch,5 Mikkael A. Sekeres,2 and Jaroslaw P. Maciejewski1,2 1Department of Translational Hematology and Oncology Research and 2Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; 3Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland; 4Department of Hematology, Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland; and 5Quantitative Health Sciences Department, Cleveland Clinic, Cleveland, OH

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Cloughesy et al.
Nature Medicine
March 2019
Authors and Affiliates
Cloughesy TF1,2,3, Mochizuki AY4, Orpilla JR5, Hugo W6, Lee AH7,5, Davidson TB8,4, Wang AC5, Ellingson BM8,9, Rytlewski JA10, Sanders CM10, Kawaguchi ES11, Du L11, Li G8,11, Yong WH12, Gaffey SC13, Cohen AL14, Mellinghoff IK15, Lee EQ13, Reardon DA13, O'Brien BJ16, Butowski NA17, Nghiemphu PL18, Clarke JL17, Arrillaga-Romany IC19, Colman H14, Kaley TJ15, de Groot JF16, Liau LM8,5, Wen PY13, Prins RM20,21,22,23. 1 Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. tcloughesy@mednet.ucla.edu. 2 Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. tcloughesy@mednet.ucla.edu. 3 Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. tcloughesy@mednet.ucla.edu. 4 Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 5 Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 6 Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 7 Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 8 Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. 9 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 10 Adaptive Biotechnologies, Seattle, WA, USA. 11 Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA. 12 Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 13 Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 14 Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. 15 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 16 Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 17 Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. 18 Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 19 Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA. 20 Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. rprins@mednet.ucla.edu. 21 Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. rprins@mednet.ucla.edu. 22 Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. rprins@mednet.ucla.edu. 23 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. rprins@mednet.ucla.edu.
Previous Next